Nine patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2036. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Sep 2036

Next term end

Patent families

When these terms end

Each bar runs from grant to computed term end. 2018 to 2043.

US 9,944,624 Substituted Amino Triazoles Useful as Human Chitinase Inhibitors Sep 2, 2036

US 10,208,020 Substituted Amino Triazoles Useful as Human Chitinase Inhibitors Sep 2, 2036

US 10,538,508 Substituted Amino Triazoles Useful as Human Chitinase Inhibitors Sep 2, 2036

US 11,638,707 Substituted Amino Triazoles Useful as Chitinase Inhibitors Jul 15, 2040

US 11,746,107 Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine Sep 25, 2040

US 12,319,677 Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine Sep 25, 2040

US 12,612,420 Arginase Inhibitors and Methods of Use Thereof Dec 22, 2041

US 12,404,279 Deubiquitinase Inhibitors and Methods of Use Thereof Dec 22, 2042

US 12,325,701 YKL-40 Inhibitors and Their Therapeutic Applications Mar 3, 2043

20232028203320382043

2 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Substituted Amino Triazoles Useful as Human Chitinase Inhibitors US 9,944,624

Granted 2018 and renewed at every maintenance window due so far. Protection runs to 2036.

Ends Sep 2036 · High confidence Also notable

Substituted Amino Triazoles Useful as Chitinase Inhibitors US 11,638,707

The newest of the three, granted 2023. It anchors the portfolio to 2040, later than anything else here.

Ends Jul 2040 · High confidence Also notable

Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine US 11,746,107

The newest of the three, granted 2023. It anchors the portfolio to 2040, later than anything else here.

Ends Sep 2040 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 5, 2027
The maintenance fee for Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine (US 11,746,107) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
1 fee due Jul 21, 2027
The maintenance fee for Substituted Amino Triazoles Useful as Human Chitinase Inhibitors (US 10,538,508) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 3 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Substituted Amino Triazoles Useful as Human Chitinase Inhibitors	3 in force	to Sep 2036
Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine	2 in force	to Sep 2040
Deubiquitinase Inhibitors and Methods of Use Thereof	1 in force	to Dec 2042

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 9,944,624	Substituted Amino Triazoles Useful as Human Chitinase Inhibitors In force Term ends Sep 2, 2036 · High confidence	In force	Term ends Sep 2, 2036	High confidence
US 10,208,020	Substituted Amino Triazoles Useful as Human Chitinase Inhibitors In force Term ends Sep 2, 2036 · High confidence	In force	Term ends Sep 2, 2036	High confidence
US 10,538,508	Substituted Amino Triazoles Useful as Human Chitinase Inhibitors In force Term ends Sep 2, 2036 · High confidence	In force	Term ends Sep 2, 2036	High confidence
US 11,638,707	Substituted Amino Triazoles Useful as Chitinase Inhibitors In force Term ends Jul 15, 2040 · High confidence	In force	Term ends Jul 15, 2040	High confidence
US 11,746,107	Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine held by Oncoarendi Therapeutics S.A. In force Term ends Sep 25, 2040 · High confidence	In force	Term ends Sep 25, 2040	High confidence
US 12,319,677	Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine In force Term ends Sep 25, 2040 · High confidence	In force	Term ends Sep 25, 2040	High confidence
US 12,612,420	Arginase Inhibitors and Methods of Use Thereof In force Term ends Dec 22, 2041 · High confidence	In force	Term ends Dec 22, 2041	High confidence
US 12,404,279	Deubiquitinase Inhibitors and Methods of Use Thereof In force Term ends Dec 22, 2042 · High confidence	In force	Term ends Dec 22, 2042	High confidence
US 12,325,701	YKL-40 Inhibitors and Their Therapeutic Applications In force Term ends Mar 3, 2043 · High confidence	In force	Term ends Mar 3, 2043	High confidence

Also on record, not counted in the 9: 2 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Molecure S.A.